

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

**Tyra Biosciences, Inc.**

---

(Name of Issuer)

**COMMON STOCK, \$0.0001 PAR VALUE PER SHARE**

---

(Title of Class of Securities)

**90240B106**

---

(CUSIP Number)

**12/31/2024**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)
- 

SCHEDULE 13G

CUSIP No. 90240B106

Names of Reporting Persons

1

Canaan XI L.P.

Check the appropriate box if a member of a Group (see instructions)

2

- (a)  
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

CAYMAN ISLANDS

	Sole Voting Power
5	3,731,165.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	3,731,165.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,731,165.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	7.4 %
12	Type of Reporting Person (See Instructions)
	PN

**Comment for Type of Reporting Person:** Based on 50,602,991 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.

## SCHEDULE 13G

**CUSIP No.** 90240B106

1	Names of Reporting Persons
	Canaan Partners XI LLC
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	3,731,165.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	3,731,165.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person

3,731,165.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

7.4 %

Type of Reporting Person (See Instructions)

12

OO

**Comment for Type of Reporting Person:** Based on 50,602,991 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.

### SCHEDULE 13G

**CUSIP No.** 90240B106

Names of Reporting Persons

1

Canaan 2020+ Co-Investment L.P. - Series 7

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

448,692.00

Number of Shares

Shared Voting Power

6

0.00

Beneficially Owned by

Sole Dispositive Power

7

448,692.00

Each Reporting Person

Shared Dispositive

With:

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

448,692.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.9 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** Based on 50,602,991 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.

SCHEDULE 13G

CUSIP No. 90240B106

1 Names of Reporting Persons  
Canaan Partners 2020+ Co-Investment LLC  
Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

5 Sole Voting Power  
448,692.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power  
0.00

7 Sole Dispositive Power  
448,692.00

8 Shared Dispositive Power  
0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
448,692.00  
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

11 Percent of class represented by amount in row (9)  
0.9 %

12 Type of Reporting Person (See Instructions)  
OO

**Comment for Type of Reporting Person:** Based on 50,602,991 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.

SCHEDULE 13G

Item 1.

(a) Name of issuer:  
Tyra Biosciences, Inc.  
Address of issuer's principal executive offices:

(b) 2656 State Street, Carlsbad, CA 92008

Item 2.

(a) Name of person filing:

(i) Canaan XI L.P., a Cayman Islands limited partnership ("Canaan XI"); (ii) Canaan Partners XI LLC, a Delaware limited liability company ("Canaan XI GP"); (iii) Canaan 2020+ Co-Investment L.P. - Series 7, a Delaware limited partnership ("Canaan Series 7"); and (iv) Canaan Partners 2020+ Co-Investment, LLC, a Delaware limited liability company ("Canaan 2020+GP").

Address or principal business office or, if none, residence:

(b) The address of the principal business office of each of the Reporting Persons is 2765 Sand Hill Road, Menlo Park, California 94025.

Citizenship:

(c) See Item 2(a) above.

Title of class of securities:

(d) COMMON STOCK, \$0.0001 PAR VALUE PER SHARE  
CUSIP No.:

(e) 90240B106

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) (i) Canaan XI directly owns 3,731,165 shares of Common Stock, which represents approximately 7.4% of the outstanding shares of Common Stock. (ii) Canaan XI GP is the general partner of Canaan XI and may be deemed to beneficially own 3,731,165 shares of Common Stock, which represents approximately 7.4% of the outstanding shares of Common Stock. (iii) Canaan Series 7 directly owns 448,692 shares of Common Stock, which represents approximately 0.9% of the outstanding shares of Common Stock. (iv) Canaan 2020+ GP is the general partner of Canaan Series 7 and may be deemed to beneficially own 448,692 shares of Common Stock, which represents approximately 0.9% of the outstanding shares of Common Stock.

Percent of class:

(b) The percent of class of the outstanding shares of Common Stock beneficially owned by the Reporting Persons in Item 4(a) are based on 50,602,991 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.  
%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(1) Canaan XI: 3,731,165 shares of Common Stock; (2) Canaan XI GP: 3,731,165 shares of Common Stock; (3) Canaan Series 7: 448,692 shares of Common Stock; and (4) Canaan 2020+ GP: 448,692 shares of Common Stock.

(ii) Shared power to vote or to direct the vote:

None.

(iii) Sole power to dispose or to direct the disposition of:

(1) Canaan XI: 3,731,165 shares of Common Stock; (2) Canaan XI GP: 3,731,165 shares of Common Stock; (3) Canaan Series 7: 448,692 shares of Common Stock; and (4) Canaan 2020+ GP: 448,692 shares of Common Stock.

(iv) Shared power to dispose or to direct the disposition of:

None.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Canaan XI L.P.

Signature: /s/ Nancy Levenson

Name/Title: Nancy Levenson, Attorney-in-Fact

Date: 01/21/2025

Canaan Partners XI LLC

Signature: /s/ Nancy Levenson

Name/Title: Nancy Levenson, Attorney-in-Fact

Date: 01/21/2025

Canaan 2020+ Co-Investment L.P. - Series 7

Signature: /s/ Nancy Levenson

Name/Title: Nancy Levenson, Attorney-in-Fact

Date: 01/21/2025

Canaan Partners 2020+ Co-Investment LLC

Signature: /s/ Nancy Levenson

Name/Title: Nancy Levenson, Attorney-in-Fact

Date: 01/21/2025